Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies
Nurmi E, Spilman S, Whelan F, Scahill L, Aman M, McDougle C, Arnold L, Handen B, Johnson C, Sukhodolsky D, Posey D, Lecavalier L, Stigler K, Ritz L, Tierney E, Vitiello B, McCracken J. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Translational Psychiatry 2013, 3: e274-e274. PMID: 23799528, PMCID: PMC3693401, DOI: 10.1038/tp.2013.26.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-Ketoglutarate-Dependent Dioxygenase FTOAmidohydrolasesAntipsychotic AgentsBody WeightChildChild Development Disorders, PervasiveChild, PreschoolFemaleGenetic Predisposition to DiseaseHumansLeptinMaleProteinsReceptor, Cannabinoid, CB1Receptor, Melanocortin, Type 4RisperidoneWeight GainConceptsWeight gainAntipsychotic-associated weight gainAntipsychotic-induced weight gainEndocannabinoid metabolic enzymesPrior adult studiesTreatment-naive populationExcessive weight gainHigh-risk groupFatty acid amide hydrolaseTreatment of irritabilityChildren/adolescentsRisperidone studyAntipsychotic exposureAdverse eventsPlasma levelsRisk groupsAdult studiesCannabinoid receptorsNetwork trialAmide hydrolasePharmacogenetic basisGene variantsSignificant riskTrend associationNaive population